Drug Trial Radar · NCT06099535
A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Oct 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
156
Actual
Start
Nov 18, 2021
Primary completion
Dec 29, 2022
Study completion Apr 11, 2023
Sponsor
- Lead sponsor
- Lynk Pharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study includes two periods. In Period 1, Participants who meet eligibility criteria will be randomized in a 1:1:1 ratio to receive a twice-daily oral LNK01001 Dose A or LNK01001 Dose B or a matching placebo for 12 weeks. Participants who receive a placebo in Period 1 will be re-randomized at Week 13 in a 1:1 ratio to receive a twice-daily oral LNK01001 Dose A or LNK01001 Dose B for 12 weeks (period 2). Participants who receive LNK01001 ( Dose A and Dose B) in Period 1 will maintain the treatment dose in Period 2.
Conditions
- Rheumatoid Arthritis
Interventions
LNK01001 Dose ADrug
Capsules taken orally
LNK01001 Dose BDrug
Capsules taken orally
placeboDrug
Capsules taken orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at week 12Time frame: week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.